Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy

European Journal of Ophthalmology

Volumn 22, Issue 3, 2012, Pages 417-422

  Rouvas, Alexandros ^a   Stavrakas, Panagiotis ^a   Theodossiadis, Panagiotis G ^a   Stamatiou, Polyxeni ^a   Milia, Maria ^a   Giannakaki, Emmanuela ^a   Datseris, Ioannis ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF WEST ATTICA   (Greece)

Author keywords

Central macular thickness; Choroidal hyperpermeability; Chronic central serous chorioretinopathy; Photodynamic therapy; Visual acuity

Indexed keywords

VERTEPORFIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CENTRAL FOVEAL THICKNESS; CENTRAL SEROUS RETINOPATHY; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; INFUSION RELATED REACTION; MALE; PATIENT SAFETY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA FOVEA; RETROSPECTIVE STUDY; SUBRETINAL FLUID; TREATMENT RESPONSE; VISUAL ACUITY;

ADULT; CENTRAL SEROUS CHORIORETINOPATHY; CHRONIC DISEASE; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84863314957     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000051     Document Type: Article

References (22)

1. Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Ho A, Orlock D. Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 1994; 112: 1057-1062.
2. Maumenee AE. Macular diseases: clinical manifestations. Trans Am Acad Ophthalmol Otolaryngol 1965; 69: 605-613.
3. Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 1967; 63 (suppl): 1-139.
4. Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol 2010; 149: 361-363.
5. Hayashi K, Hasegawa Y, Tokoro T. Indocyanine green angiography of central serous chorioretinopathy. Int Ophthalmol 1986; 9: 37-41.
6. Pryds A, Sander B, Larsen M. Characterization of subretinal fluid leakage in central serous chorioretinopathy. Invest Ophthalmol Vis Sci 2010; 51: 5853-5857.
7. Inoue R, Sawa M, Tsujikawa M, Gomi F. Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy. Am J Ophthalmol 2010; 149: 441-446.
8. Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 2003; 87: 1453-1458.
9. Piccolino FC, Borgia L, Zinicola E, Zingirian M. Indocyanine green angiographic findings in central serous chorioretinopathy. Eye 1995; 9: 324-332.
10. Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003; 23: 752-763.
11. Lee PY, Kim KS, Lee WK. Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy. Jpn J Ophthalmol 2009; 53: 52-56.
12. Treatment of age related macular degeneration with photodynamic therapy (TAP) study group. Photodynamic therapy of subfoveal choroidal neovascularization in age related macular degeneration with verteporfin. Arch Ophthalmol 1999; 117: 1329-1345.
13. Chan WM, Lai TYY, Lai RY, Tang EW, Liu DT, Lam DS. Safety enhanced photodynamic therapy for acute central serous chorioretinopathy. Retina 2008; 28: 85-93.
14. Zhao MW, Zhou P, Xiao HX, et al. Photodynamic therapy for acute central serous chorioretinopathy: the safe effective lowest dose of verteporfin. Retina 2009; 29: 1155-1161.
15. Reibaldi M, Cardascia N, Longo A, et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol 2010; 149: 307-315.
16. Shin JY, Woo SJ, Yu HG, Park KH. Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina 2011; 31: 119-126.
17. Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography- guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003; 23: 288-298.
18. Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 2008; 115: 1756-1765.
19. Lai TYY, Chan WM, Li H, Lai RYK, Liu DTL, Lam DSC. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol 2006; 90: 869-874.
20. Fujita K, Yuzawa M, Mori R. Retinal sensitivity after photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: short term results. Retina 2011; 31: 772-778.
21. Stewart JM. Half dose verteporfin PDT for central serous chorioretinopathy [editorial]. Br J Ophthalmol 2006; 90: 805-806.
22. Moon JW, Yu HG, Kim TW, Kim HC, Chung H. Prognostic factors related to photodynamic therapy for central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1315-1323.